RESONATE-2 Trial of Ibrutinib in Older Patients with Untreated CLL/SLL and the Importance of Pharmacovigilance During Ibrutinib Therapy for CLL


RESONATE-2 Trial of Ibrutinib in Older Patients with Untreated CLL/SLL and the Importance of Pharmacovigilance During Ibrutinib Therapy for CLL
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Tedeschi A et al. Results from the international, randomized Phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naïve CLL/SLL (RESONATE-2TM). Proc ASH 2015;Abstract 495.

Finnes HD et al. The importance of pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL) in routine clinical practice. Proc ASH 2015;Abstract 717.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.